Background The majority of community-acquired pneumonia (CAP) patients (about 80%)
will be treated as outpatients, because therapy with a single agent will work. For the …

Several medical-specialty professional societies have suggested that combination therapy
with a β-lactam plus a macrolide or doxycycline or monotherapy with a “respiratory …

Background: For years, monotherapy with a β-lactam antibiotic (penicillin, amoxicillin or
second-generation cephalosporin) was recommended as empirical therapy for patients with …

Scope To study the factors associated with mortality in hospitalized patients with community‐
acquired pneumonia treated with monotherapy or combination therapy. Methods PubMed …

Introduction Guidelines recommend respiratory fluoroquinolone monotherapy or β-lactam
plus macrolide combination therapy as first-line options for hospitalized adults with mild to …

Community-acquired pneumonia (CAP) is a leading cause of morbidity and mortality. This
review compared two of the main treatment alternatives: quinolone or macrolide …

Data comparing the treatment outcomes of the two most frequently recommended empirical
antibiotic regimens for community-acquired pneumonia (CAP)—combination therapy with an …

Community-acquired pneumonia (CAP) is a common and potentially serious illness that is
associated with morbidity and mortality. Although medical care has improved during the past …

OBJECTIVE: The goal of this study was to compare the outcomes of hospitalized patients
receiving a nonpseudomonal third-generation cephalosporin with or without a macrolide for …

Background: For the empirical treatment of communityacquired pneumonia requiring
admission to a non-ICU ward, the Dutch guidelines recommend either beta-lactam …